報價延遲最少15分鐘:2025/09/01 15:46 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.002 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.22/--
|
|
企業價值
23.88M
|
| 資產負債 |
|
每股賬面淨值
0.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
69.50K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/01 15:46 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator. |
